Skip to main content
SpringerLink
Log in

Unkonventionelle Heilmethoden in der Onkologie—Was gibt es Neues?

  • Zum Thema
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

Unkonventionelle Heilmethoden erfreuen sich besonders in der Onkologie zunehmender Beliebtheit. Trotz zunehmender Bemühungen um eine wissenschaftliche Erforschung einzelner Methoden konnte bisher kein ausreichender Beweis für deren Wirksamkeit und prognostische Bedeutung erbracht werden. In diesem Übersichtsartikel werden die Grundlagen und jüngeren Forschungsergebnisse zur Misteltherapie, Therapie mit Organpräparaten, Enzymtherapie, Hochdosisvitamintherapie, Selensupplementation und zu diätetischen Maßnahmen vorgestellt. Da nach wie vor das Verhältnis von Risiko und möglichen Vorteilen nicht geklärt ist, sollte sich der Einsatz der Methoden auf Studien oder dokumentierten Beobachtungen beschränken, da manche Methoden selbst schädlich sein können oder aber durch Interaktionen, z. B. mit Zytostatika, den Behandlungserfolg orthodoxer Therapien gefährden.

Abstract

Unconventional cancer therapies are becoming increasingly popular throughout the world. In spite of ongoing efforts for a scientific evaluation of these methods, so far no evidence exists on efficacy or prognostic relevance. This review summarises the basic facts and recent findings on mistletoe treatment, therapy with organ extracts, enzyme therapy, megavitamins, supplementation with selenium, and cancer related diets. Because of the unknown relationship between potential benefits and harm, the use of unconventional methods should be restricted to trials or have the intention of later analysis. These restrictions are due to the fact that harmful effects in some methods as well as pharmacological interactions with cytostatic drugs have been observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abe T, Abe Y, Aida Y, Hara Y, Maeda K (2001) Extracellular matrix regulates induction of alkaline phosphatase expression by ascorbic acid in human fibroblasts. J Cell Physiol 189: 144–151

    Article  CAS  PubMed  Google Scholar 

  2. Barrett S (2003) MICOM: The dark side of Linus Pauling's legacy. Quackwatch Web site/High dose of vitamin C are not effective as a cancer treatment. http://www.quackwatch.com

  3. Beuth J, Schierholz JM, Ko HL, Braun JM (2001) Application-dependent immunomodulating and antimetastatic efficacy of thymic peptides in BALB/c-mice. In Vivo 15: 403–406

    PubMed  CAS  Google Scholar 

  4. Beuth J, Ost B, Pakdaman A et al. (2001) Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients—results of an epidemiological multicentre retrolective cohort study. Cancer Chemother Pharmacol 47 Suppl: S45–54

    Article  Google Scholar 

  5. Boucher F, Coudray C, Tirard V et al. (1995) Oral selenium supplementation in rats reduces cardiac toxicity of adriamycin during ischemia and reperfusion. Nutrition 11: 708–711

    PubMed  CAS  Google Scholar 

  6. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340: 1733–1739

    Article  CAS  PubMed  Google Scholar 

  7. Clemente C, Belli F, Mascheroni L et al. (1996) Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients. Melanoma Res 6: 63–69

    Article  CAS  PubMed  Google Scholar 

  8. Creagan ET, Moertel CG, O'Fallon JR et al. (1979) Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301: 687–690

    Article  CAS  PubMed  Google Scholar 

  9. Dale PS, Tamhankar CP, George D, Daftary GV (2001) Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects. Cancer Chemother Pharmacol 47 Suppl: S29–34

    Article  Google Scholar 

  10. Di Lauro L, Del Medico P, Carpano S et al. (1995) Sequential subcutaneous thymopentin, interferon alpha-2a and interleukin-2 in metastatic renal cell cancer. Tumori 81: 42–44

    Article  Google Scholar 

  11. Duffield-Lillico AJ, Reid ME, Turnbull BW et al. (2002) Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11: 630–639

    PubMed  CAS  Google Scholar 

  12. Ernst E (2001) A primer of complementary and alternative medicine commonly used by cancer patients. Med J Aust 175: 88–92

    Google Scholar 

  13. Friess H, Berger HG, Kunz J, Funk N, Schilling M, Buchler MW (1996) Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Anticancer Res 16: 915–920

    PubMed  CAS  Google Scholar 

  14. Garland M, Morris JS, Stampfer MJ, Colditz GA, Spate VL, Baskett CK, Rosner B, Speizer FE, Willett WC, Hunter DJ (1995) Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 87: 497–505

    Article  CAS  PubMed  Google Scholar 

  15. Gebbia V, Valenza R, Testa A, Cannata G, Borsellino N, Gebbia N (1994) A prospective randomized trial of thymopentin vs. granulocyte--colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. Anticancer Res 14: 731–734

    PubMed  CAS  Google Scholar 

  16. Goebell PJ, Otto T, Suhr J, Rubben H (2002) Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 168: 72–75

    Article  PubMed  Google Scholar 

  17. Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R (2001) Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment. Prospective nonrandomized and randomized matched-pair studies nested with a cohort study. Altern Ther Health Med 7: 57–66

    PubMed  CAS  Google Scholar 

  18. Gujral MS, Patnaik PM, Paul R, Parikh HK, Conradt C, Tamhankar CP, Daftary GV (2001) Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers. Cancer Chemother Pharmacol 47 Suppl: S23–28

    Article  Google Scholar 

  19. Heiny B-M, Beuth J (1994) Das Lektin der Mistel als Immunmodulator: Effektorwirkung auf β-Endorphin und Zytokinfreisetzung bei Mammakarzinompatientinnen. Dtsch Zschr Onkol 26: 103–107

    Google Scholar 

  20. Heiny B-M, Albrecht V, Beuth J (1998) Lebensqualitätsstabilisierung durch Mistellektin-1 normierten Extrakt beim fortgeschrittenen kolorektalen Karzinom. Onkologe 4 (Suppl 1): S 35–39

    Article  Google Scholar 

  21. Henson DE (1999) Cancer and the Internet. Cancer 86: 373–374

    Article  CAS  PubMed  Google Scholar 

  22. Iaffaioli RV, Frasci G, Tortora G, Ciardiello F, Nuzzo F, Scala S, Pacelli R, Bianco AR (1988–89) Effect of thymic extract 'thymostimulin' on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer. Thymus 12: 69–75

    PubMed  Google Scholar 

  23. Kiremidjian-Schumacher L, Roy M, Glickman R, Schneider K, Rothstein S, Cooper J, Hochster H, Kim M, Newman R (2000) Selenium and immuncompetence in patients with head and neck cancer. Biol Trace Elem Res 73: 97–111

    Article  CAS  PubMed  Google Scholar 

  24. Kleijnen J, Knipschild P (1994) Mistletoe treatment for cancer: review of controlled trials in humans. Phytomedicine 1: 255–260

    Article  CAS  PubMed  Google Scholar 

  25. Krege S, Hinke A, Otto T, Rubben H (2002) Bewertung des Komplementärtherapeutikums Factor AF2 als Supportivum in der Behandlung des fortgeschrittenen Urothelkarzinoms. Urologe A 41: 164–168

    Article  CAS  PubMed  Google Scholar 

  26. Lamm DL, Riggs DR, Shriver JS, vanGilder PF, Rach JF, DeHaven JL (1994) Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 151: 21–26

    Article  CAS  PubMed  Google Scholar 

  27. Lenartz D, Stoffel B, Menzel J, Beuth J (1996) Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16: 3799–3802

    PubMed  CAS  Google Scholar 

  28. Loprinzi CL, Thomé SD (2001) Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 19: 972–979

    Article  CAS  PubMed  Google Scholar 

  29. Münstedt K, Entezami A, Kullmer U (2000) Onkologische Misteltherapie—zur Anwendung und Bewertung der Wirksamkeit durch Ärzte. Dtsch Med Wochenschr 125: 1222–1226

    Article  PubMed  Google Scholar 

  30. Münstedt K, Hauenschild A (2001) Ernährung und Ernährungstherapie in der Onkologie. In: Wischnik A (Hrsg) Kompendium Gynäkologie und Geburtshilfe: Weiterbildungsinhalte und Facharztstandards. Landsberg/Lech 1. Erg. Lfg 12/2001, Kap. I-10, pp1–16

  31. Münstedt K, Kirsch K, Milch W, Sachsse S, Vahrson H (1996) Unconventional cancer therapy—survey of patients with gynaecological malignancy. Arch Gynecol Obstet 258: 81–88

    PubMed  Google Scholar 

  32. Popiela T, Kulig J, Hanisch J, Bock PR (2001) Influence of a complementary treatment with oral enzymes on patients with colorectal cancers--an epidemiological retrolective cohort study. Cancer Chemother Pharmacol 47 Suppl: S55–63

    Article  Google Scholar 

  33. Risberg T, Lund E, Wist E, Kaasa S, Wilsgaard T (1998) Cancer patient use of nonproven therapy: a 5-year follow-up study. J Clin Oncol 16: 6-12

    Article  CAS  PubMed  Google Scholar 

  34. Roch CL, Demark-Wahnefried W (2002) Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 20: 3302–3316

    Article  Google Scholar 

  35. Sakalova A, Bock PR, Dedik L et al. (2001) Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma. Cancer Chemother Pharmacol 47 Suppl: S38–44

    Google Scholar 

  36. Sammon AM (1992) A case-control study of diet and social factors in cancer of the esophagus in Transkei. Cancer 69: 860–869

    Article  CAS  PubMed  Google Scholar 

  37. Singh VK, Biswas S, Mathur KB, Haq W, Garg SK, Agarwal SS (1998) Thymopentin and splenopentin as immunomodulators. Current status. Immunol Res 17: 345–368

    Article  CAS  PubMed  Google Scholar 

  38. Stauder G, Beaufort F, Streichhan P (1991) Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzympräparate. Dtsch Zschr Onkol 23: 7-16

    Google Scholar 

  39. Stettin A, Schultze JL, Stechemesser E, Berg PA (1990) Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro. Klin Wochenschr 68: 896–900

    Article  CAS  PubMed  Google Scholar 

  40. Steuer-Vogt MK, Bonkowski V, Ambrosch P, Scholz M, Neiss A, Strutz J, Hennig M, Lenarz T, Arnold W (2001) The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomized controlled clinical trial. Eur J Cancer 37: 23–31

    Article  CAS  PubMed  Google Scholar 

  41. Fujitani et al. (1973)

  42. Koyama et al. (1986)

  43. Mathijssen et al. (2002)

Download references

Author information

Authors and Affiliations

  1. Frauenklinik des Universitätsklinikums Gießen, Deutschland

    K. Münstedt & M. Zygmunt

  2. Medizinische Psychologie und Soziologie, Justus-Liebig-Universität Gießen, Deutschland

    R. von Georgi

  3. Frauenklinik des Universitätsklinikums Gießen, Klinikstraße 32, 35385 , Gießen, Deutschland

    K. Münstedt

Authors
  1. K. Münstedt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. von Georgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Zygmunt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Münstedt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Münstedt, K., von Georgi, R. & Zygmunt, M. Unkonventionelle Heilmethoden in der Onkologie—Was gibt es Neues?. Gynäkologe 36, 507–514 (2003). https://doi.org/10.1007/s00129-003-1374-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-003-1374-x

Schlüsselwörter

Keywords

Search

Navigation